Keyphrases
Parkinson's Disease
100%
Fusion Protein
100%
Granulocyte Colony-stimulating Factor (G-CSF)
100%
Extended Half-life
100%
Albumin
33%
Neuroprotective
22%
MRNA Lipid Nanoparticle
22%
Short Half-life
11%
Therapeutic Efficacy
11%
Overexpression
11%
Disease Progression
11%
Recombinant
11%
Neurodegenerative Diseases
11%
Brain Regions
11%
Neuropathology
11%
Disease-associated
11%
Synaptogenesis
11%
Immunomodulatory
11%
Patient Demographics
11%
Treg
11%
Brain Tissue
11%
Cytokine Levels
11%
Neuroprotection
11%
Injection Site Reaction
11%
Neurovascular Coupling
11%
Clinical Investigation
11%
Drug Regimen
11%
Alpha-synuclein (α-syn)
11%
Immunological Balance
11%
Plasma Cytokines
11%
Protein Modification
11%
CD4+ T
11%
Tremor
11%
Enhanced Bioavailability
11%
Low Bioavailability
11%
Nigrostriatal System
11%
Transcriptional Profile
11%
Treg Function
11%
Parkinson's Disease Model
11%
Immune Homeostasis
11%
Microglia Phenotype
11%
Gait Abnormalities
11%
Concept Evaluation
11%
Regulatory Cells
11%
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
11%
Mechanism Evaluation
11%
Low Injection
11%
MRNA-LNP
11%
Treg Frequency
11%
Pharmacology, Toxicology and Pharmaceutical Science
Fusion Protein
100%
Parkinson's Disease
100%
Granulocyte Macrophage Colony Stimulating Factor
100%
Disease
33%
Cytokine
33%
Bioavailability
22%
Mouse
22%
Neuroprotective Agent
22%
Solid Lipid Nanoparticle
22%
Combination Therapy
11%
Degenerative Disease
11%
Recombinant
11%
Physical Disease by Body Function
11%
Disease Exacerbation
11%
Injection Site Reaction
11%
Neuroprotection
11%
Alpha Synuclein
11%
1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine
11%
Biochemistry, Genetics and Molecular Biology
Fusion Protein
100%
Granulocyte Macrophage Colony-Stimulating Factor
100%
Messenger RNA
44%
Cytokine
33%
Mouse
22%
Lipid
22%
Wild Type
22%
Regulatory T Cell
22%
Homeostasis
11%
Upregulation
11%
CREB
11%
Recombinant
11%
Synaptogenesis
11%
T Cell
11%
Single Drug Dose
11%
CD4
11%
Protein Modification
11%
Alpha-Synuclein
11%
Neurovascular Coupling
11%